Market Size, Demand & Growth

The global prosthetics market was valued at roughly $13.07 billion in 2025 and is projected to reach about $23.27 billion by 2034, a compound annual growth rate near 6.62% (Market Data Forecast, 2025). A broader prosthetics-and-orthotics view from Future Market Insights, 2025 puts the combined category at $7,640.0 million in 2025 rising to $13,300.5 million by 2035 at a 5.7% CAGR, with prosthetics the faster-growing of the two segments.

Demand is structural rather than cyclical. Diabetes-related amputation, vascular disease, an ageing population, and combat and trauma cases keep the patient base growing, while microprocessor knees, myoelectric hands, and 3D-printed sockets steadily raise the average price per device. For a new manufacturer, the relevant takeaway is not the headline market size but the share served by small and mid-size makers underneath the four or five global incumbents.

The United States is the single largest market. Grand View Research, 2025 attributes 36.8% of global prosthetics-and-orthotics revenue to North America, concentrated around the large patient-care networks and the reimbursement system that funds most devices. The United Kingdom is smaller but stable: the UK prosthetics-and-orthotics market is forecast to reach roughly US$472.6 million by 2030 at a 4.4% CAGR (Grand View Research Horizon, UK), with most clinical demand running through the NHS and a handful of British manufacturers such as Blatchford.

Most market reports stop at the size table. The number that actually drives a manufacturer's plan is the gap between component cost and reimbursed price on a single high-value device, because that gap has to fund the regulatory and quality-system overhead that does not exist in a service business. We return to that figure in the unit-economics section below.

Three forces are reshaping the category in ways a current plan should reflect. Additive manufacturing has pulled the cost of custom sockets and check sockets down sharply, letting small makers compete on personalisation against incumbents tooled for volume. Microprocessor and powered components keep climbing as a share of value, which raises both the average selling price and the regulatory bar, since powered devices almost always need a 510(k) and often embedded-software validation. And demographics underwrite demand: rising diabetes and vascular disease, combined with ageing populations across North America and Europe, keep the amputee base growing independently of the economic cycle. A plan that ties its revenue ramp to one of these trends, rather than to the headline market size, is far more convincing to an investor.

Questions Founders Ask First

These come straight off the live search results for prosthetic manufacturing, answered in the order founders tend to raise them.

How much does it cost to manufacture a prosthetic limb?

The component cost of a single limb runs from a few hundred dollars for a basic cosmetic device to roughly $20,000 for the componentry inside a microprocessor knee. Finished devices sell for $5,000 to $70,000 depending on the joint, control system, and socket. The per-unit number is the easy part; the harder budget line is the fixed regulatory spend you carry before a single unit ships.

Do prosthetic devices need FDA clearance?

Most powered and microprocessor-controlled limbs are Class II and reach the US market through a 510(k) premarket notification. Even devices that are 510(k)-exempt still require their maker to hold an active FDA establishment registration, which carries a fixed annual fee of $9,280 for 2025 (Complizen, 2025).

Is prosthetics manufacturing profitable?

It can be, but the margin sits below what the device price suggests. Gross device margins of 35 to 55 percent compress to 7 to 18 percent net once research, the ISO 13485 quality system, post-market surveillance, and bundled clinical service are funded. A fabricator buying a microprocessor knee near $20,000 and supplying it at roughly a $32,000 reimbursed price keeps about $12,000 gross, which then has to cover years of fitting and maintenance for that patient (Amplitude, 2024).

What licences do you need to make prosthetics in the UK?

A UK manufacturer registers each device with the MHRA through the DORS system before placing it on the Great Britain market, applies UKCA marking after a UK Approved Body conformity assessment for Class IIa and above, and certifies its quality management system to ISO 13485:2016. The full requirements sit in the regulatory section below.

Three Device-Maker Business Models

The phrase "prosthetic device manufacturer" hides three very different businesses, each with its own capital profile and regulatory weight. Your plan should commit to one as the primary model rather than blur all three, because investors and SBA lenders price the risk differently.

A custom fabrication lab can open on six figures and reach cash-flow positive inside a year. A bionics OEM is a venture-scale build that may burn $1M or more before its first cleared sale. Picking the wrong model for your funding is the most common reason a prosthetics plan fails its first lender review.

The five global incumbents shape what is left for a new entrant, so name them honestly in the competitor section rather than pretend they do not exist. Ottobock, founded in Duderstadt, Germany in 1919, is the bionics leader, reporting record core revenue around 1.6 billion euros on the strength of its microprocessor-knee portfolio. Ossur, the Icelandic maker founded in 1971, holds roughly 23 to 24 percent of the prosthetic-components market and owns the high-performance carbon-fibre foot segment. Hanger Inc., an Austin, Texas business tracing to 1861, dominates US patient care through 700-plus clinics. Blatchford of Basingstoke (founded 1890) and Fillauer of Chattanooga (founded 1914) round out the field, the former in microprocessor limbs and the latter in upper-limb and myoelectric devices. A new manufacturer does not beat these companies on scale; it wins by serving a niche they treat as an afterthought, whether that is a specific activity level, a paediatric segment, a price point, or a turnaround clinics cannot get elsewhere.

Who Actually Buys From a Device Maker

A prosthetic device manufacturer rarely sells direct to the amputee. The buyer is almost always an intermediary, and the plan should name which one drives the majority of revenue, because each buyer has a different sales cycle, margin, and reimbursement dependency.

• Patient-care clinics and O&P practices. Independent prosthetists and groups like the 700-plus clinics Hanger operates are the largest single channel. They buy components and finished assemblies, fit them to patients, and bill payers. Winning here is about turnaround, fit reliability, and clinician trust rather than brand advertising.
• Hospitals and rehabilitation networks. These buy through procurement and value clinical evidence, durability data, and a clean regulatory file. The sales cycle is long but the contracts are sticky.
• Other manufacturers (OEM / white-label). If your edge is a single superior part, a foot, liner, or control module, selling it to larger makers can be a faster route to revenue than building a full device line.
• Veterans' and public health systems. The US Department of Veterans Affairs and the UK NHS are major buyers with formal supplier qualification. Inclusion on their frameworks can underwrite a young manufacturer's order book.

The buying trigger is almost never price alone. It is the combination of a documented clearance, predictable lead time, and outcomes evidence that lets the clinic bill the payer with confidence. Your customer-analysis section should quantify how many clinics or hospitals sit in your launch radius, what each is worth annually, and which channel converts fastest given your device class.

Geography still matters in a regulated, service-heavy category. A US launch concentrated near a metro with high clinic density, such as the Columbus or Dallas orthotics-and-prosthetics corridors, shortens the support loop on powered devices that need frequent calibration. A UK launch leaning on NHS supply frameworks behaves differently again, with procurement cycles and framework renewal dates that belong in the plan's timeline.

What It Costs to Launch

A custom fabrication lab can launch on roughly $120,000 to $250,000 (about £95,000 to £200,000). A component or bionics maker that must clear a 510(k) before selling will spend $300,000 to $750,000+ (£240,000 to £600,000+) once testing and quality systems are paid for. The headline that surprises most first-time founders is how much of that capital is regulatory rather than physical.

Cost Breakdown

• FDA establishment registration: $9,280/yr fixed (2025), required even for exempt device classes
• 510(k) clearance program (testing + user fee + consultants): $50,000-$250,000+ for a Class II device
• ISO 13485 QMS build and certification audit: $25,000-$80,000 (£20K-£65K)
• UKCA conformity assessment + UK Approved Body audit: £8,000-£40,000 (UK route)
• Fabrication equipment (CAD/CAM carvers, 3D printers, vacuum formers, lamination): $40,000-$200,000 (£32K-£160K)
• Cleanroom / controlled workshop fit-out: $30,000-$150,000 (£25K-£120K)
• Product liability + professional indemnity insurance: $8,000-$25,000/yr (£6K-£20K)
• Working capital (6 months): $40,000-$120,000 (£32K-£95K)

Two cost lines catch first-time founders off guard. The first is that the FDA establishment registration fee is flat: there is no small-business discount in 2025, so a one-person startup pays the same $9,280 as a multinational. The second is that the 510(k) figure is a range for a reason. A device that can point to a clear predicate already on the market keeps testing modest and may land near the $50,000 floor. A device with a novel mechanism, embedded software, or a new control system pushes into bench testing, biocompatibility work, and sometimes clinical data, which is how the all-in number climbs past $250,000 and, for genuinely new technology, beyond $500,000. Your plan should state which case you are in and defend the estimate, because a lender who sees a single round number with no basis assumes you have not done the work.

The UK route is cheaper at the headline level but adds a parallel obligation if you also sell into the European Union, since UKCA and CE are separate marks requiring separate conformity assessments. A manufacturer planning a Great Britain launch plus EU export should budget for both a UK Approved Body and an EU Notified Body, two technical files maintained in step, and two registrations. Folding that into the capital plan early prevents the common mid-stage surprise where European expansion stalls because the budget only ever covered one mark.

Funding a Device Manufacturer (SBA & Beyond)

Prosthetic device manufacturing maps to NAICS 339113, Surgical Appliance and Supplies Manufacturing (NAICS, 2025), whose SBA size standard is up to 800 employees, so almost every new entrant qualifies as a small business. That code opens the federal lending programs lenders actually use for capital equipment and working capital.

The routes that fit a US device maker

• SBA 504 for the equipment-heavy launch: long-term, fixed-rate financing on fabrication machinery and facility build-out, which is exactly the asset profile of a manufacturing lab.
• SBA 7(a) for general purposes and working capital. For manufacturers in NAICS sectors 31-33, the upfront guarantee fee is currently 0% on 7(a) loans of $950,000 or less (SBA manufacturing guide, 2026), a meaningful saving on the kind of mid-six-figure raise a device maker needs.
• SBA MARC revolving working capital for established manufacturers with purchase orders to finance.

In the UK, the Start Up Loans scheme offers up to £25,000 per founder at 6% fixed with free mentoring, useful seed money for a fabrication lab but far short of a bionics build. Most UK device makers combine that with Innovate UK grants, R&D tax credits, and SEIS/EIS-eligible angel investment. Across both countries, lenders want the same thing a 510(k) reviewer wants: a credible, milestone-based plan with a five-year forecast. Our bespoke business plan service builds the SBA-ready and investor-ready versions of that forecast.

The structure of the raise matters as much as the amount. Equipment is the natural fit for SBA 504 because the machinery secures the loan and the long fixed term matches the asset's life, while working capital and the regulatory program suit a 7(a) facility or equity. The mistake that kills funding rounds is asking one instrument to cover everything: a single 7(a) loan stretched across equipment, a 510(k) program, and a year of payroll leaves the business over-levered against revenue it does not yet have. A blended structure, equipment on 504, a 7(a) or angel tranche for the clearance gap, and a modest cash buffer, reads as a founder who understands both the manufacturing and the regulatory clock.

Grant capital deserves a line of its own. Medical-device innovation attracts non-dilutive funding that pure service businesses cannot reach: in the US that includes SBIR/STTR awards for novel devices, and in the UK Innovate UK and biomedical catalyst grants. These take months to win and should never be the only plank in a funding plan, but a credible grant pipeline lowers the equity a founder gives away and signals technical seriousness to later investors. The plan should list named programs, application windows, and the realistic probability and timing of each rather than treat grants as a vague upside.

Pricing, Margins & Unit Economics

Prosthetic devices are priced against reimbursement, not against a simple cost-plus markup. In the United States, Medicare pays 80% of the approved amount and the patient covers 20%, and because the catch-all L-5999 code has no fixed national rate, providers negotiate prices with payers device by device (Medicare.gov). That is why margin in this business is set at the payer table, not on the bench.

A worked unit-economics example

Take a new maker supplying microprocessor knees. Component cost is about $20,000 per unit and the reimbursed price lands near $32,000, leaving roughly $12,000 gross per device. Supply 18 units a month and that is about $216,000 in monthly gross contribution, or ~$2.6M a year before fixed costs. Subtract the QMS, post-market surveillance, R&D, insurance, and the years of bundled fitting and maintenance each device carries, and net margin settles in the 7-18% band typical of the sector.

Revenue streams to model

• Device sales to clinics, hospitals, and patient-care networks (the core line)
• Components and spare parts sold to other fabrication labs at OEM margins
• Service, calibration, and warranty contracts on powered devices over their 3-5 year life
• Licensing or white-label of a proprietary socket, liner, or control system

A plan that only models headline device revenue will overstate cash. The realistic version separates the gross-per-unit gap from the multi-year service obligation tied to each microprocessor device, because that obligation is what eats the apparent markup.

Reimbursement risk is the variable that most deserves a sensitivity analysis. Because the L-5999 catch-all has no fixed national rate, two clinics can be reimbursed very differently for the same device, and payer policy can shift between budget cycles. A robust forecast models a base case, a downside where reimbursement tightens 10 to 15 percent, and an upside where a clearance or outcomes study lifts the achievable price. Showing that the business survives the downside, rather than only the optimistic line, is exactly the discipline an SBA lender or institutional investor is looking for in a regulated-products plan.

Operations, Supply Chain & Quality

Operations is where a device maker either earns its margin or loses it. Unlike a service business, a manufacturer carries a bill of materials, a controlled production process, and a documented quality trail on every unit. The plan should show that you understand the flow from raw stock to a shipped, traceable device.

The production flow

• Design controls and design history file. Every device starts as a documented design under your ISO 13485 system, with verification and validation evidence retained for audit.
• Sourcing. Carbon fibre, titanium adaptors, electronic control modules, batteries, and liners come from a qualified supplier list. Single-sourcing a critical component is a risk auditors and investors both flag.
• Fabrication. CAD/CAM carving, additive printing of sockets, lamination, and assembly happen in a controlled workshop with calibrated equipment and recorded process parameters.
• Inspection and release. Each unit passes a documented quality check before it is released with a device identifier, so any field issue can be traced to a batch.
• Post-market surveillance. Complaints, adverse events, and field performance feed back into the design loop and, in the US, into eMDR reporting.

Lead time is a competitive weapon. Clinics choose suppliers that can turn a custom socket in days, not weeks, so the operations plan should state target turnaround by product line and the capacity that supports it. The staffing model usually pairs certified prosthetists or fabrication technicians with a quality lead and, for powered devices, an electronics or software engineer. Headcount and capacity should scale with the revenue ramp rather than sit fully loaded from day one.

Go-to-market

Marketing a regulated device is relationship-led, not advertising-led. The credible channels are clinical conferences and trade bodies, direct outreach to orthotics-and-prosthetics clinics and hospital procurement, peer-reviewed or white-paper outcomes evidence, and qualification onto VA or NHS supplier frameworks. A device maker that plans to win on paid search or social advertising signals to investors that it does not understand its buyer. The plan should map a 12 to 18 month commercial ramp tied to clearance milestones, because you cannot legally promote a device before it is cleared.

Milestones that should anchor the timeline

Because the regulatory clock governs cash, the operations and timeline sections should share the same milestone spine. A realistic sequence runs: incorporate and register the FDA establishment; stand up the ISO 13485 quality system and design controls; freeze the design and run verification and validation testing; compile and submit the 510(k); secure reimbursement coding in parallel; clear the device; then ramp production and commercial outreach. Each milestone has a cost and a date, and the funding tranches should release against them. When a plan presents this as a single Gantt line tied to the cash forecast, a lender can see exactly where the risk sits and what each dollar buys, which is the difference between a plan that gets read and one that gets funded.

Capacity planning deserves the same rigour. A workshop that can fabricate forty custom sockets a month has a different staffing and equipment footprint than one targeting four hundred components, and the plan should show the step changes, the second carver, the additional technician, the larger lamination bay, that each capacity tier requires. Modelling capacity as a smooth line understates the lumpy capital the business will actually need, and that gap tends to surface at the worst possible moment, mid-ramp, when the order book is finally growing.

Regulatory Clearance by Country

Regulation is the moat and the cost gate in this business. The plan should name the exact pathway, body, and timeline for each market you intend to sell into, because lenders and investors read this section as a proxy for whether you understand the industry at all.

United States

• FDA establishment registration + device listing with CDRH; $9,280 annual fee for FY2025, required even for 510(k)-exempt classes
• 510(k) premarket notification for most Class II powered and microprocessor limbs; FDA review targets ~90 days, full program 6-18 months
• Quality System Regulation (21 CFR 820), now aligning to ISO 13485 under the QMSR transition
• Adverse-event reporting through electronic Medical Device Reporting (eMDR)
• Reimbursement coding (HCPCS L-codes) secured before you scale inventory

United Kingdom

• Register each device with the MHRA via the DORS system before Great Britain market access (UK MDR 2002)
• UKCA marking after a UK Approved Body conformity assessment for Class IIa and above
• ISO 13485:2016 quality-management certification by an accredited body
• Appoint a UK Responsible Person (UKRP) if the manufacturer has no UK legal presence
• Technical file / design dossier, Declaration of Conformity, and clinical evidence where applicable

Other Jurisdictions

• European Union: CE marking under MDR 2017/745, Notified Body assessment, EUDAMED registration, and an EU Authorised Representative
• Canada: Health Canada MDEL/MDL with ISO 13485 audited under the MDSAP single-audit program

Note that UKCA and CE are not interchangeable post-Brexit: selling into both Great Britain and the EU means running two conformity routes, a fact that has to be in your cost model from day one.

Device classification sets everything else

Before any of these pathways applies, you have to classify the device correctly, because classification determines the conformity route, the evidence burden, and the timeline. A simple cosmetic cover sits at a lower class than a load-bearing structural limb, which sits below a powered, software-controlled knee. In the US the FDA classifies most prosthetic components as Class II, cleared through the 510(k) predicate route, while a genuinely novel device with no predicate may need the De Novo pathway or, rarely, full premarket approval. In the UK and EU the rules-based classification under the relevant MDR places most powered limbs at Class IIa or IIb, triggering an Approved Body or Notified Body audit. Getting this wrong is not a paperwork error; it can mean months of rework and a funding round that runs dry while the file is rebuilt to the correct class.

The plan should therefore name the intended class for each product line, the predicate device you will cite where one exists, and the standard testing battery the class implies, whether that is mechanical fatigue testing to the relevant ISO standard, biocompatibility for skin-contact components, or electrical-safety and software validation for powered devices. Spelling this out is the clearest signal to an investor or lender that the founder has read the regulation rather than skimmed a blog summary of it.

Mistakes That Sink First Plans

Across device-maker plans we review, the same five errors recur and each one is fatal to a lender or investor read.

• Treating it as a workshop. Ignoring the FDA 510(k) and establishment-registration gate before first sale is the most expensive oversight in the sector.
• Building inventory before securing reimbursement codes. Without the HCPCS L-codes (or negotiating the L-5999 catch-all), finished devices cannot be billed and cash stalls.
• Underbudgeting the quality system. ISO 13485, design controls, and post-market surveillance are continuous costs, not a one-off certificate.
• Confusing a patient-care clinic with a registered manufacturer. They are different legal entities with different obligations; investors notice when a plan blurs them.
• Assuming UKCA and CE are the same mark. Selling into both Great Britain and the EU requires two separate conformity routes and two budgets.

Sample Business Plan Preview

An extract from a prosthetic device manufacturer plan written by our team, so you can see the level of detail you get:

What's in the Template

Every Avvale business plan template includes these sections, pre-structured for a prosthetic device manufacturer:

• Executive Summary, Your device, model, and clearance pathway in a single investor-ready page
• Company Overview, Legal structure, FDA establishment registration, ownership, and founding story
• Industry Analysis, Market size, growth, and the regulatory environment for Class II devices
• Customer Analysis, Clinics, hospitals, patient-care networks, and payer dynamics
• Competitor Analysis, Mapping against incumbents like Ottobock, Ossur, Hanger, Blatchford, and Fillauer
• Regulatory & Quality Plan, 510(k) / UKCA pathway, ISO 13485, and post-market surveillance
• Operations Plan, Fabrication workflow, supply chain, staffing, and key milestones
• Management Team, Founder bios, clinical and engineering credentials, and key hires

The optional Financial Forecast add-on (included in our $300/£250 and $1,000/£800 packages) provides a 5-year Excel model with income statement, cash flow, balance sheet, break-even analysis, and a regulatory-spend schedule sequenced against funding tranches. See our market research and content service for the research-backed version, or browse all free business plan templates. Building something adjacent? Our 3D printing medical devices business plan template covers the additive-manufacturing route many socket makers now use.

Frequently Asked Questions